Clinical Trials Logo
  1. Home
  2. Cervical Squamous Cell Carcinoma
  3. NCT04976478

Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma

Cervical Squamous Cell Carcinoma Clinical Trial

Official title:
A Perspective, Multi-center, Single Arm Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma

Clinical Trial Summary

To evaluate the efficacy and safety of Nimotuzumab combined with IMRT in elder patients with locally advanced cervical squamous cell carcinoma

Clinical Trial Description

This is a perspective, multi-center, open-label and single arm study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04976478
Study type Observational [Patient Registry]
Source Peking University Third Hospital
Contact Junjie Wang, MD
Phone 010-82266699
Email junjiewang_edu@sina.com
Status Not yet recruiting
Phase
Start date July 2021
Completion date December 2026
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05013268 - Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma Phase 1
Completed NCT02562729 - Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Phase 2
Completed NCT00416455 - Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Phase 1/Phase 2
Completed NCT00054444 - Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer Phase 1
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Completed NCT01759355 - Hybrid PET/MR in the Therapy of Cervical Cancer
Completed NCT00068549 - Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Phase 1
Active, not recruiting NCT03983954 - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00559377 - FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Phase 2
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Active, not recruiting NCT05613283 - Primary Cervical Cancer Screening by Self-sampling HPV Test
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02466971 - Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Phase 3
Completed NCT02164461 - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Phase 1
Completed NCT01807546 - Oral Rigosertib for Squamous Cell Carcinoma Phase 2
Completed NCT00031993 - Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix Phase 2
Active, not recruiting NCT01649089 - Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer N/A
Completed NCT00499031 - Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Terminated NCT00070317 - Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer N/A
Active, not recruiting NCT03738228 - Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Phase 1